The stock of Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) hit a new 52-week low and has $6.91 target or 12.00% below today’s $7.85 share price. The 8 months bearish chart indicates high risk for the $60.34M company. The 1-year low was reported on Nov, 7 by Barchart.com. If the $6.91 price target is reached, the company will be worth $7.24M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. The stock decreased 18.06% or $1.73 on November 7, hitting $7.85. About 33,640 shares traded hands or 358.06% up from the average. Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) has risen 6.00% since October 8, 2016 and is uptrending. It has outperformed by 4.04% the S&P500.
According to Zacks Investment Research, “Spring Bank Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of therapeutics using its proprietary small molecule nucleic acid hybrid chemistry platform. The company is developing SB 9200, for the treatment of viral diseases, including hepatitis B virus. Spring Bank Pharmaceuticals, Inc. is based in Hopkinton, United States.”
More notable recent Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) news were published by: Marketwatch.com which released: “Spring Bank Pharmaceuticals Inc.” on January 07, 2016, also Prnewswire.com with their article: “Spring Bank Pharmaceuticals Appoints Martin Driscoll as President and Chief …” published on August 17, 2015, Marketwatch.com published: “Spring Bank Pharmaceuticals starts trading below issue price” on May 06, 2016. More interesting news about Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) were released by: Globenewswire.com and their article: “Spring Bank Pharmaceuticals, Inc. to Present at the 18th Annual Rodman …” published on August 22, 2016 as well as Globenewswire.com‘s news article titled: “Spring Bank Pharmaceuticals Announces Second Quarter 2016 Financial Results …” with publication date: August 01, 2016.
SBPH Company Profile
Spring Bank Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Firm is engaged in the discovery and development of therapeutics using its small molecule nucleic acid hybrid (SMNH), chemistry platform. The Company’s SMNH compounds are small divisions of nucleic acids that the Company creates to selectively target and modulate the activity of specific proteins implicated in various disease states. The Firm is developing its advanced SMNH product candidate, SB 9200, for the treatment of viral diseases. The Firm has designed SB 9200 to selectively activate within infected cells the cellular proteins retinoic acid-inducible gene 1 (RIG-I), and nucleotide-binding oligomerization domain-containing protein 2 (NOD2), to inhibit viral replication and to cause the induction of intracellular interferon signaling pathways for antiviral defense.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.